UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2015

AETHLON MEDICAL, INC.
(Exact name of registrant as specified in its charter)

Nevada	001-37487	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

9635 Granite Ridge Drive, Suite 100 San Diego, California (Address of principal executive offices)	92123 (Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by the registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to the registrant or the registrant's management identify forward-looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, the registrant's operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the registrant believes that the expectations reflected in the forward-looking statements are reasonable, the registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 7.01 REGULATION FD DISCLOSURE.

Today, September 10, 2015, Mr. James Joyce, Chief Executive Officer of Aethlon Medical, Inc. (the "Company"), presented at the Rodman & Renshaw 17th Annual Global Investment Conference. A link to the presentation may be accessed on the Company's website under the investor relations section of the website. The website address is www.aethlonmedical.com. No portion of the website shall be deemed to be incorporated into this Current Report on Form 8-K.

Among other topics discussed in the presentation, Mr. Joyce provided a brief update on near term corporate objectives identified during the Company's earnings release call held on August 13, 2015, as follows:

- The Company has received verbal confirmation from the Defense Advanced Research Projects Agency (DARPA) that its multi-year contract with DARPA will be renewed for an additional one-year period. While the Company has been informally advised that the contract will be renewed for the additional one-year period, there can be no assurance that written confirmation of renewal will be delivered to the Company or that the terms of the contract will not be modified.
- The Company has initiated its clinical study at the National Institute of Virology (NIV) in India to test the Aethlon Hemopurifier® as a candidate to treat Chikungunya, a debilitating mosquito borne virus. NIV is one of the major institutes of the Indian Council of Medical Research and is a World Health Organization collaborating center.
- The first patient has been enrolled in the Company's cancer study at U.C. Irvine Medical Center in California. The study will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The study endpoints include establishing baseline exosome levels and monitoring changes in circulating exosome concentration associated with tumor treatment and the association of longitudinal changes in circulating exosome concentrations with response to treatment. The clinical study will also provide data to help direct future clinical investigations of the Aethlon Hemopurifier® as a therapeutic candidate to reduce the presence of circulating tumor-derived exosomes, which are known to suppress the immune system of cancer patients and contribute to the spread of metastasis.
- A manuscript has been submitted for potential publication relating to data from the "Diagnosing and Evaluating Traumatic Encephalopathy using Clinical Tests (DETECT)" study. The DETECT study examined potential biomarkers for Chronic Traumatic Encephalopathy (CTE) by studying a sample of former professional American football players and a control group of same-age men without any history of brain trauma from contact sport involvement. In connection with the DETECT study, researchers at Exosome Sciences, Inc. (the Company's majority-owned subsidiary) have been applying proprietary techniques to isolate microscopic exosomes that transport CTE associated tau protein (tausomes) across the blood brain barrier.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) EXHIBITS

EXHIBIT NO.	DESCRIPTION
99.1	Presentation materials – Rodman & Renshaw Conference – September 10, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

Dated: September 10, 2015

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Presentation materials – Rodman & Renshaw Conference – September 10, 2015

Exhibit 99.1

FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon ADAPT™ system, the Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com

Aethlon Medical, Inc.

Rodman & Renshaw Conference

September 10, 2015

Jim Joyce
Chairman, CEO


AFFINITY BIOFILTRATION DEVICES
TO TREAT LIFE-THREATENING DISEASES
aethlon
MEDICAL, INC.


SAVE LIVES
aethlon
MEDICAL, INC.

Aethlon Details

- Clinical-stage Therapeutic Organization
- Headquartered in San Diego, California
- Nasdaq Capital Market: “AEMD”
- Market Value: ~ $60 million

Aethlon Technology Highlights

- Expansive Therapeutic Device Platform
  - Lead product provides clinical pathway into infectious disease and cancer
  - Advancing a sepsis treatment device through contracts with DARPA

The Aethlon Hemopurifier®

Single-Use Removal of Viral Pathogens from Circulation

aethlon MEDICAL, INC.


TIME
DEC. 1 / DEC. 8, 2014
THE 25 BEST INVENTIONS OF 2014
aethlon
MEDICAL, INC.


TIME
11
REMARKABLE
HEALTH
ADVANCES
FROM
2014
aethlon
MEDICAL, INC.

Rethinking the Treatment of Viral Pathogens

- Rapid virus elimination
  - Prior to cell and organ infection
  - Elution assay quantifies virus capture
- Targets viral structure vs. inhibiting replication
  - Allows broad-spectrum virus capture
- Addresses shed viral proteins
  - To augment/preserve host immune response


DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES
aethlon
MEDICAL, INC.


Can the Hemopurifier® Improve the Benefit of Drug Treatment Regimens?
aethlon
MEDICAL, INC.

Hepatitis C Virus (HCV)

Safety & Efficacy Observations



Conducted at the Medanta-Medicity Institute

aethlon MEDICAL, INC.

HCV Study Highlights

- Safely Administered in Combination with Interferon-Ribavirin Drug Regimen
- Improved Rapid Viral Response (RVR)
  - 58% RVR vs. 10.35%
    - Based on IDEAL Study of 3070 HCV patients
- Two Patients Undetectable at Day Seven
- 300 Billion Copies of HCV Captured


Can the Hemopurifier® Address Viral Pathogens
Not Treatable with Drug Therapies?
aethlon
MEDICAL, INC.

The Treatment of Ebola Virus

Frankfurt University Hospital



Special approval from The Federal Institute for Drugs and Medical Devices (BfArM)

aethlon MEDICAL, INC.



Hemopurifier® therapy administration to a comatose Ebola patient with multiple-organ failure

aethlon MEDICAL, INC.

Dr. Stefan Büttner
Holding Hemopurifier®
After Ebola Treatment

aethlon MEDICAL, INC.


Ebola Treatment Data
Presented By Dr. Helmut Geiger
American Society of Nephrology Annual Meeting
• 6.5 hour Hemopurifier® therapy administration
• Pre-treatment viral load: 400,000 copies/ml
• Post-treatment viral load: 1,000 copies/ml
• 242 million of Ebola viruses captured
• Patient recovered and returned home
aethlon
MEDICAL, INC.

Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmapheresis

- Stefan Büttner[a] Benjamin Koch[a] Olga Dolnik[b] Markus Eickmann[b] Tilo Freiwald[a] Sarah Rudolf[a] Jürgen Engel[a] Stephan Becker[b] Claudio Ronco[c] Helmut Geiger[a]
- [a] Medical Clinic III, Department of Nephrology, University Hospital Frankfurt, Frankfurt am Main, and [b] Institute of Virology, Philipps University Marburg, Marburg, Germany; [c] Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy

- Published: February 11, 2015

The Aethlon Hemopurifier®

Our Infectious Disease Opportunity

aethlon MEDICAL, INC.

Unmet Needs in Infectious Disease

- Antiviral Drug-Resistance
  - HIV & HCV
- Latent Virus Activation
  - Immune Suppression
    - Organ Transplants, Sepsis
- Bioterror & Pandemic Threats
  - Leading broad-spectrum countermeasure against known and unknown viruses


Ebola
Pandemic Influenza
West Nile
Pox Viruses
Lassa
Dengue
BIOTERROR & PANDEMIC VALIDATIONS
aethlon MEDICAL, INC.

Currently Approved Human Treatment Protocols

- U.S. Food and Drug Administration (FDA)
  - IDE Feasibility Study (10 Patient)
    - HCV Infected ESRD Patients (Study Initiated)
    - Single-site at DaVita Med Center Dialysis in Houston
    - Gateway to Pivotal Studies
  - Ebola Treatment Protocol
- Health Canada
  - Ebola Treatment Protocol


ONE MORE THING
aethlon
MEDICAL, INC.

The Aethlon Hemopurifier®

aethlon MEDICAL, INC.

SAVE LIVES

CANCER

aethlon MEDICAL, INC.

Tumor-Secreted Exosomes

Extracellular Vesicles or Circulating Microvesicles



aethlon MEDICAL, INC.


May, 2014
Trends in Molecular Medicine
"Extracellular Vesicles: Emerging Targets for Cancer Therapy"
THE HARVARD MEDICAL SCHOOL
NATIONAL CANCER INSTITUTE
UNIVERSITY OF OXFORD
MASSACHUSETTS GENERAL HOSPITAL
aethlon MEDICAL, INC.

Tumor-Secreted Exosomes
A Significant Unmet Medical Need in Cancer

- Trigger apoptosis of immune cells
- Contribute to drug and chemotherapy resistance
- Promote angiogenesis
- Seed the creation and spread of metastasis
- Exosome load correlates with stage of cancer

Clinical Progression Objectives

6-12 Months

- Complete FDA Approved IDE Study
  - Prepare pivotal study submission
- Advance HUD submissions
  - Disease conditions affecting < 4000 per yr. in the U.S.
- Advance Cancer Treatment Programs

aethlon MEDICAL, INC.

Near-Term Corporate Objectives

Outlined During Quarterly Call on 8/13/15

- Complete Principal Investigator Transition
  - IDE Study in Houston
- Secure Year-5 DARPA Contract
- Initiate New Clinical Collaborations
- Initiate Cancer Study at UC Irvine Medical Center
- Submit NFL Detect Study (CTE Tausome® Data) Manuscript for Publication (Exosome Sciences)

Near-Term Corporate Objectives

Outlined During Quarterly Call on 8/13/15

PROGRESS SINCE

- Secure Year-5 DARPA Contract
  - Received Verbal Confirmation of Contract Renewal
- Initiate New Clinical Collaborations
  - Initiated Chikungunya Virus Capture Study
- Initiate Cancer Study at UC Irvine Medical Center
  - First Patient Enrolled (Ovarian Cancer)
- Submit NFL Detect Study (CTE Tausome® Data) Manuscript for Publication (Exosome Sciences)
  - Submitted


AFFINITY BIOFILTRATION DEVICES
TO TREAT LIFE-THREATENING DISEASES
aethlon
MEDICAL, INC.


OUR LEAD PRODUCT PROVIDES A CLINICAL PATHWAY
TO ADDRESS INFECTIOUS DISEASE & CANCER
aethlon
MEDICAL, INC.


SAVE LIVES
aethlon
MEDICAL, INC.